CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Feb. 23, 2021–Bio-Rad Laboratories announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR assay kits were granted emergency use authorization by the FDA.
The multi-target Reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit simultaneously detects and differentiates SARS-CoV-2, influenza A, and influenza B in a single multiplex reaction. The highly sensitive respiratory pathogen panel is intended for use with nasopharyngeal swabs and anterior nasal swabs. The kit includes Bio-Rad positive and negative molecular controls.
Pages: 1 2